An update on the safety of insulin-GLP-1 receptor agonist combinations in type 2 diabetes mellitus
Language English Country Great Britain, England Media print-electronic
Document type Journal Article
- Keywords
- Basal insulin (bi), fixed-ratio insulin-glp-1 receptor agonist combination (frc), glucagon-like peptide-1 receptor agonist (glp-1 ra), hypoglycemia, insulin degludec, insulin glargine, liraglutide, lixisenatide, type 2 diabetes (t2dm), weight loss,
- MeSH
- Glucagon-Like Peptide-1 Receptor Agonists MeSH
- Diabetes Mellitus, Type 2 * drug therapy MeSH
- Drug Combinations MeSH
- Glycated Hemoglobin MeSH
- Hypoglycemia * chemically induced MeSH
- Hypoglycemic Agents adverse effects MeSH
- Insulin Glargine therapeutic use MeSH
- Blood Glucose MeSH
- Humans MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Glucagon-Like Peptide-1 Receptor Agonists MeSH
- Drug Combinations MeSH
- Glycated Hemoglobin A MeSH
- Hypoglycemic Agents MeSH
- Insulin Glargine MeSH
- Blood Glucose MeSH
INTRODUCTION: Recent development of novel antidiabetic drugs with proven cardiovascular (CV) and renal benefit and positive effect on body weight enable to take a more complex approach toward the management of type 2 diabetes mellitus (T2DM). Fixed-ratio combinations of insulin-GLP-1 receptor agonist (FRC) utilize complementary mechanisms of action of their individual components and address multiple pathologies linked with T2DM at the same time. AREAS COVERED: There are currently three FRCs on the market: iGlarLixi (glargine and lixisenatide in 2 different formulations) and IDegLira (degludec and liraglutide). We provide an up-to-date review on the rationale for the use of FRCs and their current position in the management of T2DM. We discuss the available evidence from randomized controlled trials, post hoc analyses, indirect comparative studies and real-world data on their effect on glycemic control, risk of hypoglycemia, body weight, CV safety, and their safety profile. EXPERT OPINION: FRCs represent an efficacious option for treatment intensification from basal insulin or even the first insulin-based therapy in T2DM. Their excellent glucose-lowering efficacy is complemented with lower risk of hypoglycemia in comparison to basal insulin, neutral effect on body weight and the lower risk of gastrointestinal adverse effects in comparison to GLP-1 receptor agonists.
1st Faculty of Medicine Charles University Prague Czech Republic
Department of Oncology and Metabolism University of Sheffield Sheffield UK
Diabetes Centre Institute for Clinical and Experimental Medicine Prague Czech Republic
References provided by Crossref.org
